scholarly journals Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs

2012 ◽  
pp. 391 ◽  
Author(s):  
Sabine Maes ◽  
Pype ◽  
Hoffmann ◽  
Theo Meert ◽  
Maria Biermans
Keyword(s):  
Guinea Pigs ◽  
Inflammatory Pain ◽  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

Organ culture as a model for investigating the effects of antimetabolites and nucleoside transport inhibitors on rodent colonic mucosa

1991 ◽  
Vol 27 (11) ◽  
pp. 873-877
Author(s):  
M. Moorghen ◽  
P. Ince ◽  
Karen J. Finney ◽  
A. J. Watson ◽  
A. L. Harris
Keyword(s):  
Organ Culture ◽  
Colonic Mucosa ◽  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011

2002 ◽  
Vol 13 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Christopher R Boyer ◽  
Patricia L Karjian ◽  
Geoffrey M Wahl ◽  
Mark Pegram ◽  
Saskia TC Neuteboom
Keyword(s):  
Antitumor Activity ◽  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

Steroid hormones are novel nucleoside transport inhibitors by competition with nucleosides for their transporters

2014 ◽  
Vol 443 (2) ◽  
pp. 505-510 ◽  
Author(s):  
Masahiro Kaneko ◽  
Fumihiko Hakuno ◽  
Hiroyasu Kamei ◽  
Daisuke Yamanaka ◽  
Kazuhiro Chida ◽  
...  
Keyword(s):  
Steroid Hormones ◽  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

Comparative Pharmacology of Nucleoside Transport Inhibitors

1991 ◽  
Vol 10 (5) ◽  
pp. 975-982 ◽  
Author(s):  
H. Van Belle ◽  
P. A. J. Janssen
Keyword(s):  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

Novel Nucleoside Transport Inhibitors of Natural Origin

1995 ◽  
pp. 779-782 ◽  
Author(s):  
Yong-Su Zhen ◽  
Jian Su ◽  
Yu-Chuan Xue ◽  
Chang-Qing Qi ◽  
Ji-Lan Hu
Keyword(s):  
Nucleoside Transport ◽  
Natural Origin ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors

scholarly journals Sensitization of Hematopoietic Stem and Progenitor Cells to Trimetrexate Using Nucleoside Transport Inhibitors

Blood ◽  
1997 ◽  
Vol 90 (9) ◽  
pp. 3546-3554 ◽  
Author(s):  
James A. Allay ◽  
H. Trent Spencer ◽  
Sarah L. Wilkinson ◽  
Judith A. Belt ◽  
Raymond L. Blakley ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Nucleoside Transport ◽  
Hematopoietic Stem ◽  
Myeloid Progenitor Cells ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors ◽  
Myeloid Progenitors

Abstract Antifolates such as methotrexate (MTX) and trimetrexate (TMTX) are widely used in the treatment of cancer and nonmalignant disorders. Transient, yet sometimes severe myelosuppression is an important limitation to the use of these drugs. It has previously been shown that clonogenic myeloid progenitors and colony-forming units-spleen are resistant to antifolates, suggesting that myelotoxicity occurs late in hematopoietic development. The goal of this study was to define the mechanisms by which primitive hematopoietic cells resist the toxic effects of antifolate drugs. To test the hypothesis that myeloid progenitors may salvage extracellular nucleotide precursors to resist TMTX toxicity, a defined liquid culture system was developed to measure TMTX toxicity in expanding progenitor populations. These in vitro experiments showed that both human and murine progenitors can resist TMTX toxicity by importing thymidine and hypoxanthine from the serum. As predicted from these findings, several drugs that block thymidine transport sensitized progenitors to TMTX in vitro, although to differing degrees. These nucleoside transport inhibitors were used to test whether progenitors and hematopoietic stem cells (HSCs) could be sensitized to TMTX in vivo. Treatment of mice with TMTX and nitrobenzylmercaptopurineriboside phosphate (NBMPR-P), a potent transport inhibitor, caused significant depletions of clonogenic progenitors within the bone marrow (20-fold) and spleen (6-fold). Furthermore, NBMPR-P administration dramatically sensitized HSCs to TMTX, with dual-treated mice showing a greater than 90% reduction in bone marrow repopulating activity. These studies demonstrate that both myeloid progenitor cells and HSCs resist TMTX by using nucleotide salvage mechanisms and that these pathways can be pharmacologically blocked in vivo using nucleoside transport inhibitors. These results have important implications regarding the use of transport inhibitors for cancer therapy and for using variants of dihydrofolate reductase for in vivo selection of genetically modified HSCs.

Nucleoside Transport Inhibitors Enhance the Infarct Size-Limiting Effect of Ischemic Preconditioning

1994 ◽  
Vol 24 (5) ◽  
pp. 846-852 ◽  
Author(s):  
Masao Itoya ◽  
Tetsuji Miura ◽  
Jun Sakamoto ◽  
Kazuyuki Urabe ◽  
Osamu Iimura
Keyword(s):  
Infarct Size ◽  
Ischemic Preconditioning ◽  
Nucleoside Transport ◽  
Nucleoside Transport Inhibitors ◽  
Transport Inhibitors
Sign in / Sign up

Export Citation Format

Share Document